iShares Biotechnology ETF

ProShare Advisors Increases Gilead Stake by 39.1% in Q4, Total Holdings Reach 2.2 Million Shares

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

Truist Financial Cuts Regeneron Price Target, Sending Shares Gap Down

Regeneron's fianlimab combination fails Phase 3, shares plunge over 11%

Regeneron Partners with Parabilis for $125M Deal to Advance Antibody Conjugates

Insmed's New Drug BRINSUPRI Sales Surge 44%, CEO Lewis Reaffirms Growth Confidence

Revolution Medicines Pancreatic Cancer Drug Trial Shows Positive Results, US Cancer Center Launches Expanded Access Plan Amid Stock Fluctuation

Gilead Sciences Focuses on HIV Growth and Expands Oncology and Inflammation Pipeline via Acquisitions

Natera Co-founder Sheena Jonathan Sells Shares in Two Transactions in May

Regeneron Provides Update on Phase 3 Trial of Fianlimab Combination for Melanoma

Signatera™ CDx Receives FDA Approval as Companion Diagnostic for Muscle-Invasive Bladder Cancer

Oppenheimer Raises Biogen Price Target to $300, Maintains Outperform Rating

Gilead Sciences Prices $3 Billion Senior Unsecured Bond Offering

TD Cowen Reaffirms Buy Rating on Biogen with $215 Price Target

Biogen Finalizes Acquisition Agreements with Apellis: Establishes SYFOVRE Milestone CVR and Secures $2 Billion Loan

Biogen Advances Alzheimer's Drug to Late Trials Despite Mid-Stage Failure, Shares Jump 6%

Biogen Announces Positive Phase 2 Results for Ionis Partner Drug Diranersen in Alzheimer's Disease

Biogen announces Alzheimer's drug fails to meet primary endpoint in mid-stage trial

US Clinics Race to Enroll Patients in Revolution Medicines Pancreatic Cancer Drug Early Access Plan After FDA Approval

Gilead's Yeztugo Revenues Surged 73% QoQ, Exceeding Market Expectations

Amesite

InMed Pharmaceuticals

Meiwu Tech

Co-Diagnostics

Phoenix Asia

Generation Income Properties

MetaVia

BAYVIEW ACQUISITION CORPORATION COM USD0.0001 (S/R) 17/11/2028

Virax Biolabs

Rubico

Pinned News

置顶新闻

EXCLUSIVE: Hoth Therapeutics To Rebrand To Pursue AI Chip Technologies

HOTH

LABU

Hoth Therapeutics Inc. plans to rebrand as Rocket One Inc. to focus on AI semiconductor technologies and ultra-low-power AI computing. The board unanimously approved this strategic shift, which includes securing exclusive rights to technologies from Virginia Commonwealth University. The company will maintain its biotechnology operations while addressing AI infrastructure challenges. Hoth's shares fell 9.69% to $0.55 in premarket trading, reflecting a 20.9% decline over the past month.

benzinga_article

Hoth Therapeutics

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

S&P 500

UCBJY

IBBQ

SBIO

ARKG

UCB announced positive results from the phase 3 BE BOLD trial, showing bimekizumab outperformed risankizumab in treating active psoriatic arthritis. At week 16, 49.1% of bimekizumab patients achieved ACR50 compared to 38.4% for risankizumab. Early improvements were noted as early as week 4. No new safety concerns were reported, although mild to moderate candida infections were more common with bimekizumab.

PharmaTimes

UCB S.A.

United Community Banks

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

iShares US Pharma

VG Health

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

UCB reports positive outcomes for bimekizumab in psoriatic arthritis

AMIX

A revolutionary technology has been developed that allows for minimally invasive transvascular access to nerve targets and tissues. This innovative method enables access through and beyond the lumen wall, providing a less invasive approach for procedures. This breakthrough is set to significantly improve treatment options for patients, with a success rate of over 90% in initial clinical trials. This technology is expected to benefit a wide range of medical fields and has the potential to transform minimally invasive procedures globally.

Unusual Whales

Autonomix Medical

iShares US Medical Devices

SPDR S&P Health Equip

Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation

IBRX

ImmunityBio presented analyses at the AUA 2026 meeting showing that ANKTIVA plus BCG resulted in higher complete response rates and longer-lasting benefits compared to nadofaragene in BCG-unresponsive non-muscle invasive bladder cancer. The combination also demonstrated a cleaner safety profile against TAR-200. However, the data were derived from cross-trial comparisons, which may affect interpretation by investors and clinicians.

PUBT

ImmunityBio

ImmunityBio reports higher complete response rates for ANKTIVA plus BCG in AUA analysis

Nexalin has completed the acquisition of the PONM digital health platform from GreenLight Ventures for $1.3 million, paid in Nexalin stock. The deal includes an exclusive license for AI-enabled software features and supports a planned FDA trial for HALO Clarity. GreenLight will also become an equity holder and provide ongoing support.

Nexalin Tech

NEXALIN TECHNOLOGY INC C/WTS 22/09/25(TO PUR COM)

Nexalin closes acquisition of PONM digital health platform for USD 1.3 million

RNXT

RenovoRx (RNXT) reported a record Q1 2026 revenue of $563,000, a 136% increase from Q4 2025. The company has expanded its commercial cancer centers to 16 and aims for 36 by year-end. Management reiterated a 2026 revenue target of $3-4 million, supported by a strong pipeline and cash position of $12.4 million. The TIGER-PACT Phase III trial is nearing completion, with 93% of patient enrollment achieved. Operating expenses are expected to remain stable, facilitating further revenue growth.

Motley Fool

RenovoRx

RenovoRx (RNXT) Q1 2026 Earnings Transcript

ENTA

Enanta Pharmaceuticals Inc. (ENTA) is showcasing its investigational programs, Zelicapavir and EPS-3903, at the ATS International Conference. Zelicapavir is an oral antiviral targeting the N-protein for treating respiratory syncytial virus, disrupting viral replication directly.

rttnews

Enanta Pharma

Enanta Pharma's RSV Bet And Immunology Ambitions

Radnor Capital Management LLC increased its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 130.6% in Q4, now holding 6,000 shares valued at $1.65 million. Other institutional investors also raised their positions. West Pharmaceutical's stock opened at $304.31, with a market cap of $21.50 billion and a P/E ratio of 40.68. The company reported strong earnings, beating estimates, and announced a $1 billion stock repurchase plan.

Market Beat

West Pharmaceutical

Arcadian Asset

Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST

EDSA

Edesa Biotech will present new clinical data on paridiprubart for acute kidney injury at the 63rd European Renal Association Congress in Glasgow from June 3-6, 2026. The analysis indicates a significant reduction in mortality among patients with acute kidney injury, suggesting a potential targeted therapy. An oral presentation is scheduled for June 5, 2026.

Edesa Biotech

Edesa Biotech presents new paridiprubart acute kidney injury data at ERA Congress

BAYN

BAYRY

Bayer AG announced that the U.S. FDA has granted Priority Review for Asundexian, an oral Factor Xla inhibitor aimed at preventing secondary strokes. This follows positive results from the Phase 3 OCEANIC-STROKE trial. The Priority Review designation highlights the urgency for new secondary stroke prevention methods. Stroke is a leading cause of death in the U.S., with 795,000 cases annually. Bayer's stock closed at $11.02, up 1.10%.

nasdaq

Bayer AG

Bayer

Nasdaq

Bayer Aktiengesellschaft

Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention

TLSA

Tiziana Life Sciences reported positive data from its expanded-access program for intranasal foralumab in 14 patients with non-active secondary progressive multiple sclerosis. The treatment was well tolerated, with no new safety concerns, and patients showed trends toward stabilizing disability and improvements in fatigue. The company supports further development but notes the small dataset limits conclusions.

Tiziana Life Sciences

Tiziana reports positive expanded-access data for intranasal foralumab in non-active SPMS

iShares Biotechnology ETF(IBB.US)